444325-69-3Relevant academic research and scientific papers
Design, synthesis and evaluation of constrained tetrahydroimidazopyrimidine derivatives as antagonists of corticotropin-releasing factor type 1 receptor (CRF1R)
Vrudhula, Vivekananda M.,Dasgupta, Bireshwar,Pin, Sokhom S.,Burris, Kevin D.,Balanda, Lynn A.,Fung, Lawrence K.,Fiedler, Tracey,Browman, Kaitlin E.,Taber, Matthew T.,Zhang, Jie,Macor, John E.,Dubowchik, Gene M.
scheme or table, p. 1905 - 1909 (2010/07/04)
Several tetrahydroimidazopyrimidines were prepared using silver assisted cyclization as the key step. The binding affinities of compounds thus prepared were evaluated in vitro toward hCRF1R. Initial lead compound 16 (Ki = 32 nM) demo
Imidazolyl derivatives as corticotropin releasing factor inhibitors
-
, (2008/06/13)
The present invention relates to novel heterocyclic antagonists of Formula (I) and pharmaceutical compositions comprising said antagonists of the corticotropin releasing factor receptor (“CRF receptor”) useful for the treatment of depression, anxiety, affective disorders, feeding disorders, post-traumatic stress disorder, headache, drug addiction, inflammatory disorders, drug or alcohol withdrawal symptoms and other conditions the treatment of which can be effected by the antagonism of the CRF-1 receptor.
